Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells

• 主要な著者: Chao-Yue Sun (著者), Milton Talukder (著者), Di Cao (著者), Cun-Wu Chen (著者)
• フォーマット: 図書
• 出版事項: Frontiers Media S.A., 2022-06-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Abemaciclib is a cyclin-dependent kinases 4/6 (CDK4/6) inhibitor approved for the treatment of metastatic breast cancer. Preclinical studies suggest that abemaciclib has the potential for lung cancer treatment. However, several clinical trials demonstrate that monotherapy with abemaciclib has no obv...